Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy

Abstract Background and aim The objective of this retrospective, observational, noninterventional cohort study was to investigate prognostic factors of overall survival (OS) in patients with advanced non‐small cell lung cancer (aNSCLC) and to develop a novel prognostic model. Methods A total of 4049...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Cristina Julian, Robson J. M. Machado, Sandhya Girish, Pascal Chanu, Dominik Heinzmann, Chris Harbron, Anda Gershon, Shannon M. Pfeiffer, Wei Zou, Valerie Quarmby, Qing Zhang, Yachi Chen
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wiley 2022-10-01
Ráidu:	Cancer Reports
Fáttát:	advanced NSCLC immune checkpoint inhibitors prognostic model real‐world data
Liŋkkat:	https://doi.org/10.1002/cnr2.1578
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!